|
| |
EluSys Therapeutics IncorporatedEluSys Therapeutics, Inc. is focused on the development and commercialization of the EluSys Heteropolymer System (the "Technology" or "HP System"), a novel platform technology to treat a wide variety of blood-borne infections and autoimmune diseases. The HP System should enable the rapid, safe and efficient removal and destruction of viral particles, bacteria, toxins and autoantibodies from the bloodstream by injecting a therapeutic compound into the patient. The HP System may be tailored to remove and destroy members of the major classes of blood-borne pathogen within several hours of administration, thus potentially providing an effective treatment for a broad array of different diseases.
| Contact Details: |
| 10 Bloomfield AvenueP.O. Box 102 |
| Pine Brook |
| NJ |
| 07058 |
| United States of America |
| Tel: | 973-808-0222 |
| Fax: | 973-808-0322 |
| Email: | Info@EluSys.com |
| WWW: | www.elusys.com/
|
|
Loading...
|
Recent Publications by EluSys Therapeutics Incorporated: |  |
Purification of antibody heteropolymers using hydrophobic interaction chromatography.
A heteropolymer (HP) is a unique dual antibody conjugate composed of... | 7th March, 2008
| Elusys Therapeutics Inc., 25 Riverside Drive, Pine Brook, NJ 07058, USA.
| J Chromatogr A. 2008 Jan 11;1177(2):254-64. Epub 2007 Oct 13.
DOI Direct Link |
A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation.
Complement-dependent cytotoxicity (CDC) is a key mechanism of Rituximab... | 31st December, 2005
| Elusys Therapeutics, 25 Riverside Drive, PO Box 102, Pine Brook, NJ 07058,
| Cancer Immunol Immunother. 2005 Dec;54(12):1172-9. Epub 2005 Apr 22.
DOI Direct Link |
Heteropolymers: a novel technology against blood-borne infections.
Heteropolymer (HP) technology is a novel cassette technology which is... | 29th June, 2005
| Elusys Therapeutics Inc, 25 Riverside Drive, Pine Brook, NJ 07058, USA.
| Curr Opin Mol Ther. 2005 Apr;7(2):144-50.
|
A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.
We have developed a therapeutic for the treatment of anthrax using an... | 12th March, 2005
| Elusys Therapeutics Inc., P.O. Box 102, 25 Riverside Drive, Pine Brook, NJ
| Infect Immun. 2005 Feb;73(2):795-802.
DOI Direct Link |
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.
We investigated the ability of using monoclonal antibodies (MAbs) against... | 24th June, 2004
| Elusys Therapeutics, Inc., Pine Brook, New Jersey 07058, USA.
| Infect Immun. 2004 Jun;72(6):3276-83.
DOI Direct Link |
→View more EluSys Therapeutics Incorporated research publications. |
 Contact BioPortfolio for a quote for a customised Excel verision of BioCorporate or BioEmail databases.
This page has been viewed 408 times since April 2007, the link to the organisation's website has been followed 55 times Recent Search Terms used to find this page: elusys | 25 Riverside Drive Pine Brook NJ 07058 | elusys ther | elusys ther | . Search for more companies in Pine Brook Search for more companies in NJ This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified.BioPortfolio search results for EluSys Therapeutics Incorporated |
